View Older Stories View More Recent Stories

Dec 10, 2015 09:00AM Johnson & Johnson Announces Formation Of Verb Surgical Inc., In Collaboration With Verily
Dec 7, 2015 04:38PM Johnson & Johnson (JNJ) IMBRUVICA Ph-3 RAY Data Shows Significant Improvements in PFS Versus Temsirolimus in Patients with r/r Mantle Cell Lymphoma
Dec 7, 2015 04:36PM Data from IMBRUVICA Phase 2 RESONATE-17 Presented at ASH 2015; High ORR Noted (JNJ) (ABBV)
Dec 7, 2015 04:30PM IMBRUVICA® (ibrutinib) Phase 2 RESONATE-17 Data Show Robust Clinical Activity and Promising Survival Outcomes in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with del 17p
Dec 7, 2015 08:35AM IMBRUVICA® (ibrutinib) Phase 3 RAY Data Show Significant Improvements in Progression-Free Survival Versus Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Dec 7, 2015 07:16AM AbbVie (ABBV) Announces Positive ORR Data from Ibrutinib Combo Phase 2 as FL Treatment
Dec 7, 2015 06:19AM Janssen Announces Phase 3 RESONATETM-2 Met All Efficacy Endpoints
Dec 6, 2015 11:05AM Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Treatment-Naïve Patients with Chronic Lymphocytic Leukaemia
Nov 30, 2015 08:00AM Janssen Submits Applications Seeking Approval Of STELARA® In United States And European Union For Crohn's Disease
Nov 24, 2015 08:44PM Share A Photo, Give Back In A Snap
Nov 17, 2015 01:08PM BabyCenter Research Reveals That While Moms Show Strong Interest In 'Sharing Economy' Services, 'On-Demand' Apps Need To Be Better Marketed To Reach Them
Nov 16, 2015 04:58PM DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
Nov 13, 2015 08:05AM Additional Efficacy and Safety Data for IMBRUVICA® (Ibrutinib) Submitted to FDA
Nov 13, 2015 08:00AM Largest Schizophrenia and Schizoaffective Disorder Caregiver Survey Reveals Overwhelming Burden and Inadequate Assistance
Nov 13, 2015 07:35AM New EIU report challenges policy response to diabetes epidemic in the Gulf region
Nov 4, 2015 08:21AM Janssen Data Presentations At American College of Rheumatology Meeting Showcase Commitment To Rheumatologic Diseases
Oct 23, 2015 01:45PM Janssen (JNJ) Announces FDA Approval of YONDELIS For Treatment of Patients With Unresectable or Metastatic Liposarcoma or Leiomyosarcoma
Oct 23, 2015 01:42PM U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma
Oct 19, 2015 08:10AM Phase 3 Data Show STELARA® Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn's Disease
Oct 13, 2015 05:23PM Market Wrap: Job Cuts Aplenty at Twitter; Intel Tops Q3 Expectations; Analysts Get Bearish on GoPro
Oct 5, 2015 10:24AM Notable Analyst Rating Changes 10/5: (TWTR) (FOLD) (JNPR) Upgraded; (SNI) (LRCX) (FEYE) Downgraded
Sep 28, 2015 10:45AM First data from Europe’s first and largest prospective observational study of metastatic castration-resistant prostate cancer (mCRPC) presented at the 2015 European Cancer Congress (ECC2015)
Sep 15, 2015 06:01PM Janssen: New pan-European survey reveals that only 14% of healthcare professionals feel sufficiently equipped to address prostate cancer patients’ quality of life issues
Sep 14, 2015 08:40AM IMBRUVICA® (ibrutinib) Supplemental New Drug Application for Treatment-naive Chronic Lymphocytic Leukemia Submitted to the U.S. FDA
Sep 8, 2015 08:00AM Your Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV Community Organizations
Sep 2, 2015 09:06AM U.S. FDA Approves Update of SIMPONI ARIA® (golimumab for infusion) Label to Include Improvement in Both Physical and Emotional Measures of Health When Treating Moderately to Severely Active Rheumatoi
Aug 21, 2015 02:00AM Janssen Submits European Extension Marketing Authorisation Application for Paliperidone Palmitate Once-Every-Three-Months Formulation
Aug 12, 2015 03:05AM Johnson & Johnson Innovation Announces Collaboration on Immuno-Oncology Antibody ADC-1013 with Alligator Bioscience
Jul 23, 2015 05:43PM Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir
Jul 14, 2015 05:22PM Market Wrap: DJIA Climbs Back Over 18k; Retail Sales Miss in June; Twitter Gets Active on False Hope
Jul 8, 2015 05:00PM Phase 2b Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis
Jun 30, 2015 08:00AM It's Time to Act on Obesity: Ethicon Expands Commitment To Help Reverse The Devastating Impact Of Metabolic Diseases
Jun 25, 2015 08:57AM INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available
Jun 5, 2015 11:50AM Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
May 20, 2015 07:30AM Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue
May 19, 2015 05:25PM Market Wrap: Housing Starts Rip in April; Achillion Enters Key HCV Pact; IRS May Stymie Yahoo!'s Asset Spin Plans
May 19, 2015 08:00AM U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia
May 19, 2015 08:00AM U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia
May 13, 2015 05:22PM Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at ASCO (JNJ)
May 13, 2015 05:09PM Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11, 2015 05:47PM U.S. FDA Issues Complete Response Letter to sNDA Seeking to Expand the Label for INVEGA SUSTENNA®
Apr 16, 2015 09:00AM Ethicon Receives Prestigious Awards for Innovation in Design, Sustainability Improvements
Apr 15, 2015 08:30AM Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia
Apr 6, 2015 08:00AM FDA Expands Indication for EVARREST® Fibrin Sealant Patch
Apr 1, 2015 08:00AM Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C
Mar 30, 2015 09:00AM New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia
Mar 29, 2015 02:31AM New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia
Mar 27, 2015 08:00AM Johnson & Johnson to Webcast Annual Meeting of Shareholders
Mar 21, 2015 05:46AM Data Presented at the 30th European Association of Urology (EAU) Congress Further Assesses Efficacy, Safety and Tolerability of ZYTIGA® (Abiraterone Acetate) in Both Pre- and Post- Chemotherapy Setti
Mar 10, 2015 10:57AM EVARREST® Fibrin Sealant Patch a Potential Solution for Aortic Reconstruction Surgery
View More Recent Stories View Older Stories